Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.58 |
| ▸ | JAK1 | P23458 | 9/20 | 0.58 |
| ▸ | TYK2 | P29597 | 8/20 | 0.58 |
| ▸ | JAK3 | P52333 | 6/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.54 |
| ▸ | PRKDC | P78527 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ITK | Q08881 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2571182 | 0.90 | JAK2 (0.57) | JAK2JAK1TYK2JAK3PIK3CB | |
| SCHEMBL2569373 | 0.88 | PIK3CB (0.50) | JAK2JAK1TYK2JAK3PIK3CB | |
| SCHEMBL2574834 | 0.85 | JAK1 (0.57) | JAK2JAK1TYK2JAK3MAPT | |
| SCHEMBL2574416 | 0.79 | JAK2 (0.61) | JAK2JAK1TYK2JAK3MAPT | |
| SCHEMBL13632606 | 0.77 | JAK2 (0.63) | JAK2PIK3CBPRKDCMAPTMEN1 | |
| SCHEMBL2577729 | 0.76 | PRKDC (0.57) | JAK2PIK3CBPRKDCMAPTSMN1; SMN2 | |
| SCHEMBL13859374 | 0.75 | JAK2 (0.69) | JAK2MAPTITKMAPK1PLK4 | |
| SCHEMBL16514799 | 0.75 | JAK2 (0.66) | JAK2ITKPLK4 | |
| SCHEMBL2574100 | 0.74 | JAK1 (1.00) | JAK2JAK1TYK2JAK3LMNA | |
| SCHEMBL2574808 | 0.73 | JAK1 (0.69) | JAK2JAK1TYK2JAK3FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629168-B2 | Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors | NOVARTIS AG (CH) | 2014-01-14 | — | — | US | claimed |
| EP-2066647-B1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2011-11-09 | — | — | EP | claimed |
| US-20100009978-A1 | Benzoxazoles and Oxazolopyridines Being Useful as Janus Kinases Inhibitors | NOVARTIS AG | 2010-01-14 | — | — | US | claimed |
| US-8629168-B2 | Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors | NOVARTIS AG (CH) | 2014-01-14 | — | — | US | disclosed |
| US-8629168-B2 | Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors | NOVARTIS AG (CH) | 2014-01-14 | — | — | US | disclosed |
| EP-2066647-B1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2011-11-09 | — | — | EP | disclosed |
| US-20100009978-A1 | Benzoxazoles and Oxazolopyridines Being Useful as Janus Kinases Inhibitors | NOVARTIS AG | 2010-01-14 | — | — | US | disclosed |
| US-20100009978-A1 | Benzoxazoles and Oxazolopyridines Being Useful as Janus Kinases Inhibitors | NOVARTIS AG | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009978-A1 | Benzoxazoles and Oxazolopyridines Being Useful as Janus Kinases Inhibitors | JAK2, JAK3, JAK1 | JAK2 1/4885JAK1 3/4885TYK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.